Document is current
Any future updates will be listed below
-
Authors
Welte, Tamara M.
Gabriel, Maria
Hopfengärtner, Rüdiger
Rampp, Stefan
Gollwitzer, Stephanie
Lang, Johannes D.
Stritzelberger, Jenny
Reindl, Caroline
Madžar, Dominik
Sprügel, Maximilian I.
Huttner, Hagen B.
Kuramatsu, Joji B.
Schwab, Stefan
Hamer, Hajo M.
-
Funding
Funding for this research was provided by:
Universitätsklinikum Erlangen
- License Information
-
More Information
Article History
Received: 20 September 2021
Accepted: 15 April 2022
First Online: 4 May 2022
Competing interests
: SG reports personal fees from Desitin, Eisai, UCB, outside the submitted work. DM reports grants from UCBPharma and BayerVitalGmbH, outside submitted work. MIS reports grants from IZKF and Marohn Foundation outside submitted work. HBH reports grants from Novartis, grants and personal fees from Bayer AG, grants and personal fees from Daiichi Sankyo, grants and personal fees from Medtronic, grants and personal fees from Portola Pharmaceuticals, outside the submitted work. HMH reports personal fees from UCB, Desitin, Eisai, GW, Novartis, IQWiG, Hexal, facetoface, grants from Amgen, Ad-Tech, Bracco, Pfizer, Micromed, Nihon Kohden, personal fees from Arvelle, outside the submitted work. TMW, MG, RH, SR, JDL, JS, CR, JBK, SS declare that they have no competing interests.
